Harvard Bioscience Q3 revenue rises 8%, beats estimates

Overview

• Life science tech developer's Q3 revenue grew 8% yr/yr, beating analyst expectations

• Net loss for Q3 widened compared to prior year

• Company reaffirmed full-year 2026 revenue growth guidance of 3%-5%

Outlook

• Company expects Q4 revenue between $23.7 mln and $25.5 mln

• Company sees Q4 adjusted gross margin between 59% and 61%

• Harvard Bioscience reaffirms full-year 2026 revenue growth guidance of 3%-5%

Result Drivers

• CHINA AND CRO SALES - Co said double-digit revenue growth to contract research organizations and customers in China drove Q3 topline increase

• PRODUCT DEMAND - Co cited ongoing demand for organoids, respiratory, and fluidics products as supporting Q3 revenue growth

• HIGHER EXPENSES - Higher expenses related to sales and administration contributed to wider net loss

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Harvard Bioscience Inc is $10.25, about 12.8% above its November 9 closing price of $9.09

Reuters Recommended Reads

• Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%

• Nov 9 - Quanterix Q3 revenue rises 6.3% sequentially

• Nov 10 - MaxCyte looks to acquire Akron Bio to expand cell therapy manufacturing; Q3 revenue rises

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)